Home

Federal Government Relations

BIO and USPTO Trace the Journey of Biotech Inventions

BIO will be co-hosting an event with the United States Patent and Trademark Office (USPTO) to celebrate the 30th anniversary of the issuance of U.S. patent 4,259,444 to Ananda Chakrabarty following the Supreme Court case, Diamond v. Chakrabarty, which held that Chakrabarty’s bioengineered bacterium was eligible for patenting.

New Report Shows Monoclonal Antibody Development Times Are Lengthening

A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant.

The Cost of Losing Innovation

Current rules resulting from a 2003 Office of Hearings and Appeals decision have inhibited and interfered with the growth and survival of small private biotechnology companies and the development of promising technologies and products

Moving Forward: USDA Awards Additional Loan Guarantees for Refineries

The Agriculture Department has announced additional money for loan guarantees to support construction of new advanced biofuel biorefineries.

World Health Day: The Global Impact of Vaccines

As we celebrate World Health Day today, it is an opportunity to remember that vaccines represent one of the most important global health investments.

FDA Funding: Budget Increase Sought for 2012

President’s call for more funding comes as Congress focuses on reducing budget deficits.

Senate committee marks up SBIR/STTR reauthorization
Patent Reform Passes the Senate and Moves to the House

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

Budgets & Biotech: Congress Urged to Continue Supporting Advanced Biofuels

Industry leaders point out that biotech-enabled advanced biofuels spur job growth and reduce U.S. dependence on imported oil.

Solid Results: Survey Shows Therapeutic Discovery Project Works

The government’s Qualifying Therapeutic Discovery Project Program is doing what it was intended to do, according to a recent survey of senior executives at small biotechnology companies.

Biotech Beets: USDA Lets Farmers Resume Planting

Agency issues partial deregulation of Roundup Ready sugar beets while it prepares an environmental impact statement.

What Legal Issues are Presented by Biosimilars?
The Economic Contributions of the Biotechnology Industry

This report presents the estimates of the significant financial contributions of the biotechnology industry to the U.S. economy and to revenues collected by the federal, state and local governments.

Regulatory Relief: House Passes SOX Relief Bill

In 2010, a lessening of the regulatory burden on biotech startups looks promising.

Hot or Not: Rate the FDA

Letters, Testimony & Comments

Pandemic and All-Hazards Preparedness Reauthorization Act
December 18 2012
BIO President and CEO Jim Greenwood wrote a letter in support of H.R. 6672, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2012, sponsored and championed by Chairman Mike Rogers (R-MI).
The Renewable Fuels Standard: A Successful Federal Policy that Must Be Defended
October 18 2012
A keynote Address by James C. Greenwood, President & CEO of BIO, to RETECH 2012 in Washington, DC on October 18, 2012.
IP Attache Program: BIO's Congressional Hearing Comments
June 28 2012
The U.S. Intellectual Property Rights Attaché Program has had significant success and holds immense promise in helping to enhance IP protection abroad for U.S. interests.
Oppose Costly & Confusing Labeling Amendment to the Agriculture Reform, Food and Jobs Act of 2012
June 21 2012
Senators Sanders and Boxer have introduced an amendment that will result in costly and extreme food labeling requirements.
The Farm Bill: BIO Opposes the Sanders-Boxer Amendment
June 21 2012
BIO, which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations around the world, strongly opposes the Sanders-Boxer Amendment (#2310) to the Farm Bill.
More Letters, Testimony & Comments →

Press Releases

BIO Praises House of Representatives for Passing H.R. 701
May 16 2013
H.R. 701 sets a deadline to complete rule-making on Regulation A reforms.
BIO applauds Rep. David Schweikert for Introducing Spread Pricing Liquidity Act
May 15 2013
H.R. 1952 will stimulate trading for small public companies.
BIO Applauds Reps. Hurt and Meeks for Introducing H.R. 1564 to Avoid Burdensome Regulations
April 16 2013
Bill would allow emerging biotech companies to maintain a working relationship with their independent auditor.
BIO Praises the U.S. House of Representatives for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
March 5 2013
On March 4, 2013, the U.S. House of Representatives passed PAHPRA by a vote of 370-28.
BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act
February 28 2013
BIO lauds the Senate for passing H.R. 307, the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), yesterday by a unanimous vote.
More Press Releases →